Last reviewed · How we verify
Eugene Y Rhee, MD — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Promescent Lidocaine Spray | Promescent Lidocaine Spray | phase 3 | Topical local anesthetic | Voltage-gated sodium channels | Urology / Sexual Health |
Therapeutic area mix
- Urology / Sexual Health · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- Brown, Theodore R., M.D., MPH · 1 shared drug class
- IWK Health Centre · 1 shared drug class
- The University of Texas Health Science Center, Houston · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Eugene Y Rhee, MD:
- Eugene Y Rhee, MD pipeline updates — RSS
- Eugene Y Rhee, MD pipeline updates — Atom
- Eugene Y Rhee, MD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Eugene Y Rhee, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eugene-y-rhee-md. Accessed 2026-05-18.